Lynparza (olaparib) — United Healthcare
High risk early breast cancer
Initial criteria
- Diagnosis of high risk early breast cancer
- Presence of deleterious or suspected deleterious germline BRCA-mutations (gBRCAm)
- Disease is human growth factor receptor 2 (HER2)-negative
- One of the following: Patient is hormone receptor (HR) negative OR (Patient is hormone receptor (HR) positive AND Patient is continuing concurrent treatment with endocrine therapy)
- Patient has been treated with neoadjuvant or adjuvant chemotherapy
- Treatment duration has not exceeded 12 months of therapy
Approval duration
12 months